oglemilast
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2006 (NCT00322283)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
PDE4A inhibitor
- Phosphodiesterase 4INHIBITOR
Phosphodiesterase 4 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1- Mol. weight
- 516.31 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297520 ↗
Also known as
- grc3886
- grc 3886
- grc-3886
- oglemilast
- oglemilast
- oglemilast
- oglemilast
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00859404 | Phase 2 | Oct 1, 2008 | Glenmark Pharmaceuticals |
| NCT00671073 | Phase 2 | Apr 1, 2008 | Forest Laboratories |
| NCT00322283 | Phase 2 | May 1, 2006 | Forest Laboratories |
| NCT00322686 | Phase 2 | May 1, 2006 | Forest Laboratories |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Forest Laboratories | For profit | 3 | 3 | 1 | 2006 |
| Glenmark Pharmaceuticals | For profit | 1 | 1 | 1 | 2008 |
2 organizations
Page 1 / 1